FutureMeds 2022: A Year in Review
Updated: 3 days ago
2022 has been another phenomenal year for FutureMeds. We are pleased to share the highlights of 2022, focusing on three key areas - our business, our people, and our broader clinical trial journey.
Over the past couple of years, the clinical trial industry has faced many challenges and rapid change, but through it all, the industry has remained committed to providing the highest quality services to clients and patients. Despite the obstacles, as an industry, we have continued to make significant strides in advancing medical knowledge, providing patients with access to potentially life-saving treatments and offering them the opportunity to play a more active role in their own healthcare.
As a company, being a part of this industry gives us the opportunity to be at the forefront of medical innovation and make a real difference in people's lives. It is a privilege to be able to contribute to this important work, and we are confident that together with our clients, partners, and the wider community, FutureMeds will continue to make a positive impact on patient populations worldwide.
Speaking of FutureMeds’ contribution to medical progress, we are pleased to share the highlights of 2022, focusing on three key areas - our business, our people, and our broader clinical trial journey.
FutureMeds, Our Business
At FutureMeds, our purpose is to find answers to medical problems faster, together. In addition, we strive to make a difference in our patient communities, create value for our clients, and improve our people's knowledge and access to opportunities.
2022 has been another phenomenal year for FutureMeds. We dedicated the year to improving our foundations, solidifying our people strategy and structure, evolving our culture, integrating and adapting new technology and streamlining our processes.
Our teams made important upgrades under the bonnet. We consolidated operations and implemented a single Clinical Trials Management System across all our Dedicated Research Sites. These upgrades and improvements will help us provide our clients with faster outcomes, increased study timeline protection and improved patient experience.
As part of FutureMeds’ expansion strategy, we acquired a site in Bulgaria, identified new opportunities in Germany, Spain and the Balkans and entered negotiations.
In 2023 we will focus on expanding and strengthening our strategic partnerships with clients and vendors, continuing international expansion to new countries, growing our presence in our countries, and rolling out FutureMeds Oncology-specific service.
An organisation is only as good as its people, as the adage goes. Attracting and retaining critical talent and ensuring the right people are in key roles is an essential part of our growth strategy.
In 2022, our team grew by 21% as a result of our people strategy around 2 distinct priorities:
Filling key leadership roles: we focused on finding people with the right skill set to fill key roles such as VP of Operations, VP of Business Development, VP of IT and Country Managing Directors in 2022. We managed to hire people who have in-depth knowledge of the clinical trials industry, have a track record in delivering great outcomes and results, are flexible in terms of being able to adjust to a fast-changing and complex ecosystem and, most importantly, are passionate and determined to drive progress and motivate our teams to make a difference.
Increasing team cohesion and expertise of our Dedicated Research Site teams: we doubled down on improving our capabilities and efficiencies by hiring PIs and investigators with deep domain expertise, strong leadership and communication skills and a wide network of colleagues and connections in the research community. All these enable our dedicated teams to improve collaboration in their communities, boost team performance and generate reliable and meaningful outcomes faster for our clients.
It is heartening to see that our efforts across the 2 priorities are reaping the rewards for our clients and our patient communities as we see increased staff engagement across the board and key talent joining FutureMeds to further their careers. Naturally, we recognise that we still have areas to improve, and in 2023 and onwards, we will ensure continuous effort in these areas.
Our Clinical Trial Journey
FutureMeds’ experienced investigators and Dedicated Research Sites teams helped our clients protect study timelines and successfully conducted studies in most major therapeutic areas in 2022. Key highlights:
FutureMeds Dedicated Research Sites successfully enrolled over 1600 patients
We signed 97 new studies and conducted over 400 feasibilities
FutureMeds Dedicated Research Sites achieved High-Quality Scores on all client audits with no critical or major findings
We started the first ambulatory oncology study in Poland
We launched a new mobile unit in Poland to reach up to 15,000 more patients per year
Our patient engagement teams grew our patient database by 25% through a large-scale prescreening strategy
We started our first multicountry study in UK, Poland, Bulgaria
To close, we would like to thank our patients, clients, and partners for their continued trust in FutureMeds, our people for their passion and commitment and the broader community for their support and recognition of what the dedicated teams at FutureMeds try to bring to patient populations and the wider society. FutureMeds are proud of the work we have accomplished together.
As we look ahead to the new year, to the rapid change, and increasing complexity of the clinical trial landscape, it becomes increasingly clear that working together in closer partnerships can create breakthroughs and innovations that provide solutions to the current challenges and improve patient care and experience.
At FutureMeds, we recognise our duty in the industry, and we will continue to grow and provide valuable support to set studies apart, generate outcomes faster and give diverse patient populations access to new treatments.
FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.